Blinatumomab is a BiTE antibody with variable regions recognizing both CD and CD. 적절한 T세포 활성화를 위해서는 CD와 CD 모두에 결합해야 하며 HLA 독립적인 경로에서 작용합니다. Singleagent blinatumomab was administered to patients with Bcell ALL in morphologic remission but detectable MRD.